Clinical Trial Detail

NCT ID NCT01269853
Title Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors North Shore Long Island Jewish Health System
Indications

mixed oligodendroglioma-astrocytoma

astrocytoma

glioblastoma multiforme

Therapies

Bevacizumab

Age Groups: adult

No variant requirements are available.